English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Systemic administration of drugs into the blood circulation is standard treatment for prevention of metastasis. However, systemic delivery cannot maintain sufficiently high concentrations of anticancer drugs in lymph nodes ( LN ). Here, we show that giving cisplatin ( CDDP ) using a lymphatic drug delivery system ( LDDS ) has the potential to treat false‐negative metastatic  LN . We found that in  MXH 10/Mo‐ lpr / lpr  mice, which develop systemic swelling of  LN  up to 10 mm in diameter, accumulation of indocyanine green ( ICG ), which has a similar molecular weight to  CDDP , in a target  LN  was greater for lymphatic delivery of  ICG  than for systemic (i.v.) administration. Furthermore,  CDDP  administration with a  LDDS  inhibited tumor growth in false‐negative metastatic  LN  and produced fewer adverse effects than systemically given  CDDP . We anticipate that drug delivery using a  LDDS  will, in time, replace systemic chemotherapy for the treatment of false‐negative metastatic  LN .

Therapeutic effect of cisplatin given with a lymphatic drug delivery system on false‐negative metastatic lymph nodes